- Suvorexant, sold
under the
brand name
Belsomra, is an
orexin antagonist medication which is used in the
treatment of insomnia. It is
indicated specifically...
- non-peptide
antagonist is
currently available in the U.S., Merck's
suvorexant (
Belsomra), two
additional agents are in development: SB-649,868 by GlaxoSmithKline...
- PMID 36411777. "
BELSOMRA® (suvorexant) C-IV".
Belsomra.
Retrieved 2015-10-31.
Ventura J, ed. (2014-08-31). "FDA
approves new type of
sleep drug,
Belsomra". Food...
-
Orexin antagonists Daridorexant (Quviviq)
Lemborexant (Dayvigo)
Suvorexant (
Belsomra)
First generation Antihistamines Brompheniramine (Dimetapp, Bromfed) Captodiame...
-
pulmonary disease, and
sleep apnea – half-life 17–55
hours Suvorexant (
Belsomra) – dual OX1 and OX2
antagonist –
approved for
insomnia in
August 2014,...
- to
severe pain, and in some
formulations to
treat opioid use
disorder Belsomra (Suvorexant) – used to
treat insomnia Celexa (citalopram) – an antidepressant...
- dependence.
There are
three dual
orexin receptor (DORA)
drugs on the market:
Belsomra (Merck),
Dayvigo (Eisai) and
Quviviq (Idorsia).
Certain atypical antipsychotics...
- this
effort as part of a multi-pronged "unbranded"
marketing effort for
Belsomra (suvorexant), Merck's then-forthcoming new
sleeping drug. Some merchants...
